Long-term outcomes following CAR T cell therapy: what we know so far
KM Cappell, JN Kochenderfer - Nature reviews Clinical oncology, 2023 - nature.com
Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …
CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …
[HTML][HTML] Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of
hematologic malignancies. Approximately half of patients with refractory large B cell …
hematologic malignancies. Approximately half of patients with refractory large B cell …
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
[HTML][HTML] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
Next-generation CAR T-cell therapies
RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
Advancing CAR T cell therapy through the use of multidimensional omics data
Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
treatment of certain haematological malignancies, challenges remain in optimizing CAR …